Effect of tranexamic acid in reducing blood loss during hysterectomy .
Not Applicable
- Conditions
- Health Condition 1: Z907- Acquired absence of genital organ(s)
- Registration Number
- CTRI/2020/07/026924
- Lead Sponsor
- Maulana Azad Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Women undergoing hysterectomy for benign uterine pathology.
Exclusion Criteria
Women with thrombophilia,allergy to tranexamic acid,on going hematuria, subarachnoid hemorrhage or antithrombotic treatment, Previous or active thromboembolic disease, family history of thromboembolism,underlying heart,liver ,kidney or pulmonary diease, malignant disease, previous history or family history of seizure or convulsion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain tranexamic acid's anti-fibrinolytic effects in uterine surgery?
How does intravenous tranexamic acid compare to standard hemostatic agents in hysterectomy outcomes?
Are there specific biomarkers that predict response to tranexamic acid in benign uterine pathology patients?
What are the known adverse events associated with tranexamic acid use in gynecological procedures?
What combination therapies with tranexamic acid are being explored for postpartum hemorrhage management?